R&D Trends

Pfizer, GSK, Siemens and A*STAR form R&D consortium

Monday, June 24, 2013 03:13 PM

Pfizer Asia Pacific, GlaxoSmithKline and Siemens are founding members of the A*STAR R&D consortium program Innovative Processing of Specialties and Pharmaceuticals (iPSP). Launched by A*STAR's Institute of Chemical and Engineering Sciences (ICES), the consortium is a platform for pharmaceutical and specialty chemicals industry companies to address costs, regulatory compliance and responsiveness in production and processes to bring drugs to markets.

More... »

Protalix, Brazil's Ministry of Health enter technology transfer agreement

Friday, June 21, 2013 01:31 PM

Protalix BioTherapeutics has entered into a supply and technology transfer agreement with Fundação Oswaldo Cruz (Fiocruz), an arm of the Brazilian Ministry of Health, for UPLYSO (alfataliglicerase), the company's proprietary enzyme replacement therapy for Gaucher disease. Gaucher disease is a rare lysosomal storage disorder that affects approximately 10,000 people worldwide.

More... »

Nuclea, BMC sign research agreement

Friday, June 21, 2013 01:28 PM

Nuclea Biotechnologies signed an R&D agreement with Berkshire Medical Center (BMC) that could lead to more effective treatment for prostate and breast cancer. This partnership will advance R&D biomarkers, which are a vital component in the field of personalized medicine.

More... »

Nuclea teams with SUNY for nanochip development

Friday, June 21, 2013 01:20 PM

SUNY’s College of Nanoscale Science & Engineering (CNSE) and Pittsfield, Mass.-based Nuclea Biotechnologies have launched a $1 million research partnership to enable the development and commercialization of a high-throughput nanochip to accelerate the diagnosis and treatment of breast, colon, prostate and other cancers.

More... »

JDRF, Xeris Pharmaceuticals and Latitude Pharmaceuticals partner

Friday, June 21, 2013 01:17 PM

JDRF, a global organization funding type 1 diabetes (T1D) research, has partnered with both Xeris Pharmaceuticals and Latitude Pharmaceuticals (LPI) to support the development soluble glucagon formulations—a step toward the advancement of future-generation, fully automated and multi-hormonal artificial pancreas systems for people with (T1D).

More... »

Tocagen awarded grant by Voices Against Brain Cancer

Thursday, June 20, 2013 12:52 PM

Voices Against Brain Cancer (VABC), a nonprofit organization dedicated to finding a cure for brain cancer, has awarded Tocagen, a privately held biopharmaceutical, a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4). 

More... »

Athera, Boehringer Ingelheim enter option agreement on novel therapy

Thursday, June 20, 2013 10:00 AM

Athera Biotechnologies has entered into an option agreement with Boehringer Ingelheim International on a novel preclinical antibody program, which grants Boehringer Ingelheim an exclusive option to acquire the entire program.

More... »

CollabRx, University of Chicago collaborate

Wednesday, June 19, 2013 01:50 PM

CollabRx data analytics, focused on informing clinical decision making in molecular medicine, is collaborating with the thoracic oncology program at the University of Chicago Medical Center, a cancer treatment center with clinical and translational research programs in cancer genetics and therapeutics.

More... »

Curie-Cancer, Sanofi collaborate

Wednesday, June 19, 2013 01:42 PM

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Carnot Institute, have established a three-year research collaboration to identify new therapeutic targets for developing treatments for ovarian cancer.

More... »

Ambrx, Zhejiang Medicine, WuXi PharmaTech collaborate

Tuesday, June 18, 2013 09:32 AM

Ambrx, a clinical stage biopharmaceutical company, and China-based pharmaceutical Zhejiang Medicine (ZMC) are collaborating to develop and commercialize ARX788, Ambrx’s internally developed, site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

More... »